Pill bottle-themed Lucite tombstone marking the acquisition of a royalty interest in worldwide sales of Xenpozyme. Xenpozyme has been developed and approved as a treatment for acid sphingomyelinase deficiency (ASMD). (22AKL627)
Pill bottle-themed Lucite tombstone marking the acquisition of a royalty interest in worldwide sales of Xenpozyme. Xenpozyme has been developed and approved as a treatment for acid sphingomyelinase deficiency (ASMD). (22AKL627)
Crystal deal toy, incorporating a 3D etching of a DNA strand, commemorating the merger of biotech companies Atrin Pharmaceuticals and Aprea Therapeutics. (22ALJ234)
Crystal commemorative recognizing team members in a first in-human clinical study of an anti-tumor therapy.
(9AJH024)Custom Lucite displaying advances in the corporate culture and branding of Voya Financial.
(8AMF014)Crystal commemorative celebrating a development and commercialization agreement between Click Therapeutics and pharmaceutical firm Boehringer Ingelheim. The partnership centers on a mobile prescription app providing digital treatment for patients with schizophrenia.
(21AKL599)Lucite embedment with drug vial commemorating a study of a treatment for solid tumor cancer.
(21ADH006)Lucite tombstone recognizing the sale of a majority stake in Recycla. The Italian company provides waste collection and disposal services.
(21LSS303)Lucite deal toy celebrating an investment in GC Rieber VivoMega, a Norwegian supplier of Omega-3 concentrates.
(21LJW034)Custom Lucite tombstone commemorating the acquisition of CanSource, a Colorado-based can manufacturer. Based in Longmont, CanSource specializes in serving the craft beer industry.
(20AKL273)
